Biote Reaffirms 2024 Financial Guidance, With Acceleration In H2 Growth; Sees Revenue Of $200M-$204M, Est $203.167M; Adjusted EBITDA Of $60M-$63M

3/12/24 4:52:53 PM ET

Medicinal Chemicals and Botanical Products

Health Care

Get the next $BTMD alert in real time by email

Previously, Biote projected fiscal 2024 revenue of greater than $200 million and Adjusted EBITDA of greater than $60 million. First half 2024 consolidated year-on-year revenue growth is expected to be in the low-single digits, with significant improvement expected in the second half of 2024. Total revenue growth in the first half of 2024 is expected to be impacted by the transition in the nutraceutical distribution channel and timing of seasonal promotions.

Get the next $BTMD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BTMD

Date	Price Target	Rating	Analyst
2/20/2024	$9.00	Buy	B. Riley Securities
2/1/2024		Buy	Jefferies

More analyst ratings

$BTMD
Leadership Updates

Live Leadership Updates

Biote to Purchase Asteria Health
Strategic and accretive transaction enables vertical integration of hormone product manufacturing biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive agreement to acquire F.H. Investments, Inc., d/b/a Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The company operates an FDA-registered 503B outsourcing facility in Birmingham, Alabama and currently supports Biote-certified practitioners and Biote-partnered clinics in numerous U.S. states. Through this transaction, Biote is strengt
1/17/24 4:05:00 PM ET
$BTMD
Medicinal Chemicals and Botanical Products
Health Care
Biote Names Robert Peterson as Chief Financial Officer
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Robert Peterson has been named Chief Financial Officer, effective January 8, 2024. Mr. Peterson will lead Biote's finance operations, including accounting and controllership, financial planning and analysis, financial reporting, internal audit, tax, treasury and investor relations. Mr. Peterson succeeds Samar Kamdar, who is transitioning to pursue other opportunities, but will remain as an advisor to the Company during a transition period. Mr. Kamdar's transition is unrelated to t
1/11/24 4:05:00 PM ET
$BTMD
Medicinal Chemicals and Botanical Products
Health Care
Biote Appoints Mary J. Puncochar as Chief Commercial Officer
Ms. Puncochar to Drive Execution of Biote's Strategic Sales and Marketing Initiatives biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Mary J. Puncochar as Chief Commercial Officer. In this role, Ms. Puncochar will lead Biote's commercial initiatives to expand the Company's presence in the growing market for hormone replacement therapy. Ms. Puncochar joins Biote with more than 30 years of experience in sales, tech-enabled marketing and management roles at leading healthcare, pharmaceutical and medical device companies. Prior to joining Biot
5/30/23 8:30:00 AM ET
$BTMD
Medicinal Chemicals and Botanical Products
Health Care

AccessHope Expands Executive Leadership Team Amid Rapid Growth and Upcoming Market Expansion
Duke University Oncologist and former Optum Executive Dr. Yousuf Zafar Named Chief Medical OfficerVeteran Digital Health and Commercial Leader Peter Bridges to Serve as Chief Strategy and Growth OfficerDebra Morris Promoted to PresidentDUARTE, Calif., Nov. 13, 2024 /PRNewswire/ -- AccessHope, LLC, a company changing the way leading-edge cancer expertise is delivered, today announced that it is expanding its executive leadership team in response to growing demand for the company's personalized cancer benefit and upcoming product expansion. Yousuf Zafar, MD, MHS, a widely published practicing oncologist from Duke University who brings expertise in value-based care and precision medicine, will
11/13/24 9:00:00 AM ET
$BTMD
$REXR
Medicinal Chemicals and Botanical Products
Health Care
Real Estate Investment Trusts
Real Estate
Biote Reports Third Quarter 2024 Financial Results
Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitive advantages Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $51.4 million Procedure revenue of $37.9 million Gross profit margin of 70.5% Net income of $12.7 million and diluted earnings per
11/12/24 4:05:00 PM ET
$BTMD
Medicinal Chemicals and Botanical Products
Health Care
Biote Schedules Third Quarter 2024 Financial Results Release and Conference Call
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Tuesday, November 12, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Third Quarter Earnings Call. A replay of the webcast will
10/29/24 4:05:00 PM ET
$BTMD
Medicinal Chemicals and Botanical Products
Health Care

Biote Reports Third Quarter 2024 Financial Results
Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitive advantages Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $51.4 million Procedure revenue of $37.9 million Gross profit margin of 70.5% Net income of $12.7 million and diluted earnings per
11/12/24 4:05:00 PM ET
$BTMD
Medicinal Chemicals and Botanical Products
Health Care
Biote Schedules Third Quarter 2024 Financial Results Release and Conference Call
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Tuesday, November 12, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Third Quarter Earnings Call. A replay of the webcast will
10/29/24 4:05:00 PM ET
$BTMD
Medicinal Chemicals and Botanical Products
Health Care
Biote Reports Second Quarter 2024 Financial Results
Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $49.2 million Procedure revenue of $38.4 million Gross profit margin of 68.9%, including a $1.2 million inventory step-up related to the acquisition of Asteria Healt
8/8/24 4:05:00 PM ET
$BTMD
Medicinal Chemicals and Botanical Products
Health Care

Biote Reaffirms 2024 Financial Guidance, With Acceleration In H2 Growth; Sees Revenue Of $200M-$204M, Est $203.167M; Adjusted EBITDA Of $60M-$63M

Chat with this insight

Recent Analyst Ratings for $BTMD

$BTMD Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Biote Corp.

SEC Form SC 13G/A filed by Biote Corp. (Amendment)

SEC Form SC 13G/A filed by Biote Corp. (Amendment)

$BTMD Leadership Updates

Live Leadership Updates

Biote to Purchase Asteria Health

Biote Names Robert Peterson as Chief Financial Officer

Biote Appoints Mary J. Puncochar as Chief Commercial Officer

$BTMD Press Releases

Fastest customizable press release news feed in the world

AccessHope Expands Executive Leadership Team Amid Rapid Growth and Upcoming Market Expansion

Biote Reports Third Quarter 2024 Financial Results

Biote Schedules Third Quarter 2024 Financial Results Release and Conference Call

$BTMD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Peterson Robert Charles sold $203,848 worth of shares (32,874 units at $6.20), closing all direct ownership in the company (SEC Form 4)

Chief Financial Officer Peterson Robert Charles converted options into 44,250 shares and sold $86,084 worth of shares (11,376 units at $7.57) (SEC Form 4)

Amendment: SEC Form 4 filed by Director Morris Debra L

$BTMD Market Insights

Live Market Insights

Biote Signs Binding Term Sheet With Stockholder Marci M. Donovitz To Resolve Litigation; Enters $60M Agreement To Repurchase 8.3M Shares and Cancel 4.0M Earnout Shares

Biote shares are trading lower after J Capital issued a short report on the stock.

Biote Reiterates Guidance

$BTMD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

B. Riley Securities initiated coverage on biote Corp. with a new price target

Jefferies initiated coverage on biote Corp.

$BTMD SEC Filings

$BTMD Financials

Live finance-specific insights

SEC Form 424B3 filed by Biote Corp.

SEC Form 424B3 filed by Biote Corp.

SEC Form 10-Q filed by Biote Corp.

Biote Reports Third Quarter 2024 Financial Results

Biote Schedules Third Quarter 2024 Financial Results Release and Conference Call

Biote Reports Second Quarter 2024 Financial Results

Recent Analyst Ratings for
$BTMD

$BTMD
Large Ownership Changes

$BTMD
Leadership Updates

$BTMD
Press Releases

$BTMD
Insider Trading

$BTMD
Market Insights

$BTMD
Analyst Ratings

$BTMD
SEC Filings

$BTMD
Financials